Liraglutide reduced postprandial glucose across all three daily meals by 31–49 mg/dl (1.68–2.71 mmol/l). • beta-cell function. clinical trials with liraglutide indicate improved beta-cell function based on measures such as the homeostasis model assessment for beta-cell function (homa-b) and the proinsulin to insulin ratio..
Victoza contains less than 1 mmol sodium (23 mg) per dose, therefore the medicinal product is essentially ‘sodium-free’. traceability. in order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded..
